Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded to "Hold" at Wall Street Zen

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

A number of other equities analysts also recently commented on TNXP. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday. Noble Financial restated an "outperform" rating and set a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $40.65 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals has a fifty-two week low of $6.76 and a fifty-two week high of $363.20. The stock has a 50 day moving average price of $23.21 and a two-hundred day moving average price of $23.00. The company has a market capitalization of $297.76 million, a P/E ratio of -0.01 and a beta of 2.09.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. The company had revenue of $2.43 million during the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Analysts expect that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current year.

Insider Buying and Selling at Tonix Pharmaceuticals

In other news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was acquired at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the acquisition, the chief executive officer now owns 4,005 shares in the company, valued at $86,307.75. This trade represents a 80,000.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.03% of the company's stock.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers bought a new position in Tonix Pharmaceuticals in the first quarter worth $244,000. Royal Bank of Canada bought a new position in Tonix Pharmaceuticals in the first quarter worth $610,000. Caitong International Asset Management Co. Ltd bought a new position in Tonix Pharmaceuticals in the first quarter worth $405,000. IFP Advisors Inc bought a new position in Tonix Pharmaceuticals in the first quarter worth $179,000. Finally, Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals in the fourth quarter worth $66,000. Institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.